Noile-Immune Biotech Inc. Share Price

Equities

4893

JP3759560000

Biotechnology & Medical Research

Delayed Japan Exchange 07:59:54 08/05/2024 am IST 5-day change 1st Jan Change
158 JPY +0.64% Intraday chart for Noile-Immune Biotech Inc. 0.00% -25.47%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site

Financials

Sales 2024 * 319M 2.05M 172M Sales 2025 * 319M 2.05M 172M Capitalization 6.8B 43.8M 3.66B
Net income 2024 * -851M -5.48M -458M Net income 2025 * -877M -5.65M -472M EV / Sales 2024 * 21.3 x
Net cash position 2024 * - 0 0 Net cash position 2025 * - 0 0 EV / Sales 2025 * 21.3 x
P/E ratio 2024 *
-7.99 x
P/E ratio 2025 *
-7.75 x
Employees 28
Yield 2024 *
-
Yield 2025 *
-
Free-Float 21.67%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.64%
Current month-2.47%
1 month-14.13%
3 months-14.59%
6 months-59.59%
Current year-25.47%
More quotes
1 week
155.00
Extreme 155
161.00
1 month
150.00
Extreme 150
211.00
Current year
150.00
Extreme 150
259.00
1 year
150.00
Extreme 150
775.00
3 years
150.00
Extreme 150
775.00
5 years
150.00
Extreme 150
775.00
10 years
150.00
Extreme 150
775.00
More quotes
Managers TitleAgeSince
President 56 01/16/01
Chief Administrative Officer 47 01/20/01
Director/Board Member 42 01/15/01
Members of the board TitleAgeSince
Director/Board Member 65 01/20/01
President 56 01/16/01
Director/Board Member 42 01/15/01
More insiders
Date Price Change Volume
08/24/08 158 +0.64% 60 400
07/24/07 157 -0.63% 120,900
02/24/02 158 0.00% 257,800
01/24/01 158 -2.47% 404,400

Delayed Quote Japan Exchange, May 08, 2024 at 07:59 am IST

More quotes
Noile-Immune Biotech Inc is a Japan-based company mainly engaged in the development of chimeric antigen receptor T (CAR-T) cell therapy for solid tumors using proprietary technology. The Cancer Immunotherapy Drug Discovery Business segment develops various gene-modified immuno-cell therapies for the treatment of solid tumors, mainly by combining PRIME technology, a platform technology, with therapeutic technologies targeting various antigens expressed by solid tumors. The Company establishes a hybrid business model with two business models: in-house drug discovery, in which the company takes the initiative in drug discovery, and joint pipeline, in which PRIME technology is licensed to other companies for drug development.
Calendar
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
157 JPY
Average target price
440 JPY
Spread / Average Target
+180.25%
Consensus

Annual profits - Rate of surprise

-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW